USSTOCK.TODAY
Regular Market
Log in Sign up

Helus Pharma shares plunge 21% despite positive Phase 3 clinical results

Investing.com +2 · ·by G4L

HELP
HELP Helus Pharma Inc
$8.87 +0.11%
View chart & analysis →
  1. 1Helus Pharma Inc. shares fell 21% on Monday.
  2. 2HLP003 recorded a 7.6-point improvement from MADRS baseline compared to placebo at week 6.
  3. 3HLP003 showed a 5.0-point reduction from MADRS baseline compared to placebo as early as day 2.

So what's the key point?

Helus Pharma announced results showing the drug is effective, but the stock price fell 21%. This means the share price dropped significantly even though the drug's improvement results were released.

Source Investing.com +2 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →